Combination approaches with immune checkpoint blockade in cancer therapy

Combination approaches with immune checkpoint blockade in cancer therapy

Blog Article

In healthy individuals, pemko 173a immune checkpoint molecules prevent autoimmune responses and limit immune cell-mediated tissue damage.Tumors frequently exploit these molecules to evade eradication by the immune system.Over the past years, immune checkpoint blockade of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) emerged as promising strategies to activate anti-tumor cytotoxic T cell responses.Although complete hlpro4sw regression and long-term survival is achieved in some patients, not all patients respond.This review describes promising, novel combination approaches involving immune checkpoint blockade, aimed at increasing response-rates to the single treatments.